Table 1.
Clinical characteristics
| Gestational age, wks (mean ± SD) | 38.7 ± 1.5 |
| Birth weight, kg (mean ± SD) | 3.3 ± 0.7 |
| Male gender (n, %) | 37 (50) |
| Apgar score | |
| 1 min (median, range) | 1 (0–9) |
| 5 mina (median, range) | 3 (0–9) |
| 10 minb (median, range) | 5 (0–10) |
| Initial pH (median, range) | 6.95 (6.50–7.42) |
| Encephalopathy grade at presentation (Modified Sarnat) | |
| Moderate (n, %) | 55 (74) |
| Severe (n, %) | 19 (26) |
| EEG seizures (n, %) | 9 (12) |
| Received phenobarbital (n, %) | 19 (26) |
| Received vasoactives (n, %) | 33 (45) |
| Dopamine (n, %) | 33 (45) |
| Epinephrine (n, %) | 4 (5) |
| Age at MRI (median, range)c | 10 (3–18) |
| Respiratory Support (n, %) | 66 (89) |
| High Frequency Ventilator (n, %) | 7 (9) |
| Conventional Ventilator (n, %) | 39 (53) |
| Other (n, %) | 20 (27) |
| None (n, %) | 8 (11) |
| Respiratory Rate | |
| Conventional Ventilator (median, interquartile range) | 22 (16–28) |
| Spontaneous Breathing (median, interquartile range) | 31 (25–36) |
| HFOV | n/a |
| Heart Rate Overall (median, interquartile range) | 110 (99–128) |
| Group 0 | 103 (96–124) |
| Group 1 | 109 (96–120) |
| Group 2 | 106 (100–135) |
| Group 3 | 116 (107–131) |
| Group 4 | 127 (114–145) |
a
Documented for 73/74 infants;
b
Documented for 64/74 infants,
c
Documented for 65/74 infants,